BBOT — BridgeBio Oncology Therapeutics, Inc. Dilution Risk Tracker

BridgeBio Oncology Therapeutics, Inc. (BBOT) has a DilutionScore of 52/100, placing it in the High dilution risk tier. This score reflects at least one active dilution mechanism — a shelf registration, ATM program, outstanding warrants, or limited cash runway — that could materially increase the share count over the next 12–18 months. Score as of July 14, 2026, updated from SEC EDGAR data.

DilutionWatch's EDGAR monitoring for BBOT shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for BBOT in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for BBOT alongside comparable high-risk stocks. Not financial advice — this analysis is for informational purposes only.